Literature DB >> 10074165

Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines.

P Polacino1, V Stallard, D C Montefiori, C R Brown, B A Richardson, W R Morton, R E Benveniste, S L Hu.   

Abstract

We previously reported that immunization with recombinant simian immunodeficiency virus SIVmne envelope (gp160) vaccines protected macaques against intravenous challenge by the cloned homologous virus E11S but that this protection was only partially effective against the uncloned virus, SIVmne. In the present study, we examine the protective efficacy of this immunization regimen against infection by a mucosal route. We found that the same gp160-based vaccines were highly effective against intrarectal infection not only with the E11S clone but also with the uncloned SIVmne. Protection against mucosal infection is therefore achievable by parenteral immunization with recombinant envelope vaccines. Protection appears to correlate with high levels of SIV-specific antibodies and, in animals protected against the uncloned virus, the presence of serum-neutralizing activities. To understand the basis for the differential efficacies against the uncloned virus by the intravenous versus the intrarectal routes, we examined viral sequences recovered from the peripheral blood mononuclear cells of animals early after infection by both routes. We previously showed that the majority (85%) of the uncloned SIVmne challenge stock contained V1 sequences homologous to the molecular clone from which the vaccines were made (E11S type), with the remainder (15%) containing multiple conserved changes (the variant types). In contrast to intravenously infected animals, from which either E11S-type or the variant type V1 sequences could be recovered in significant proportions, animals infected intrarectally had predominantly E11S-type sequences. Preferential transmission or amplification of the E11S-type viruses may therefore account in part for the enhanced efficacy of the recombinant gp160 vaccines against the uncloned virus challenge by the intrarectal route compared with the intravenous route.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074165      PMCID: PMC104075     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Characterization of clones of HIV-1 infected HuT 78 cells defective in gag gene processing and of SIV clones producing large amounts of envelope glycoprotein.

Authors:  R E Benveniste; R W Hill; L J Eron; U M Csaikl; W B Knott; L E Henderson; R C Sowder; K Nagashima; M A Gonda
Journal:  J Med Primatol       Date:  1990       Impact factor: 0.667

2.  HIV-1 genomic RNA diversification following sexual and parenteral virus transmission.

Authors:  T F Wolfs; G Zwart; M Bakker; J Goudsmit
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

3.  Intrarectal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus.

Authors:  M P Cranage; A Baskerville; L A Ashworth; M Dennis; N Cook; S Sharpe; G Farrar; J Rose; P A Kitchin; P J Greenaway
Journal:  Lancet       Date:  1992-02-01       Impact factor: 79.321

4.  Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen.

Authors:  P Polacino; V Stallard; J E Klaniecki; D C Montefiori; A J Langlois; B A Richardson; J Overbaugh; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  Molecular characterization and comparison of simian immunodeficiency virus isolates from macaques, mangabeys, and African green monkeys.

Authors:  R E Benveniste; D Raben; R W Hill; W B Knott; J E Drummond; L O Arthur; P B Jahrling; W R Morton; L E Henderson; G Heidecker
Journal:  J Med Primatol       Date:  1989       Impact factor: 0.667

6.  Isolation of a lentivirus from a macaque with lymphoma: comparison with HTLV-III/LAV and other lentiviruses.

Authors:  R E Benveniste; L O Arthur; C C Tsai; R Sowder; T D Copeland; L E Henderson; S Oroszlan
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

7.  Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants.

Authors:  S M Wolinsky; C M Wike; B T Korber; C Hutto; W P Parks; L L Rosenblum; K J Kunstman; M R Furtado; J L Muñoz
Journal:  Science       Date:  1992-02-28       Impact factor: 47.728

8.  Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

Authors:  S L Hu; K Abrams; G N Barber; P Moran; J M Zarling; A J Langlois; L Kuller; W R Morton; R E Benveniste
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

9.  Inoculation of baboons and macaques with simian immunodeficiency virus/Mne, a primate lentivirus closely related to human immunodeficiency virus type 2.

Authors:  R E Benveniste; W R Morton; E A Clark; C C Tsai; H D Ochs; J M Ward; L Kuller; W B Knott; R W Hill; M J Gale
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

10.  Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.

Authors:  J Klaniecki; T Dykers; B Travis; R Schmitt; M Wain; A Watson; P Sridhar; J McClure; B Morein; J T Ulrich
Journal:  AIDS Res Hum Retroviruses       Date:  1991-10       Impact factor: 2.205

View more
  22 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Authors:  R J Gorelick; R E Benveniste; J D Lifson; J L Yovandich; W R Morton; L Kuller; B M Flynn; B A Fisher; J L Rossio; M Piatak; J W Bess; L E Henderson; L O Arthur
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

4.  Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection.

Authors:  Christopher W Peterson; Patrick Younan; Patricia S Polacino; Nicholas J Maurice; Hannah W Miller; Martin Prlic; Keith R Jerome; Ann E Woolfrey; Shiu-Lok Hu; Hans-Peter Kiem
Journal:  J Med Primatol       Date:  2013-10       Impact factor: 0.667

5.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Authors:  Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

6.  SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma.

Authors:  Zhong-Min Ma; Brandon F Keele; Huma Qureshi; Mars Stone; Veronique Desilva; Linda Fritts; Jeffrey D Lifson; Christopher J Miller
Journal:  AIDS Res Hum Retroviruses       Date:  2011-07-06       Impact factor: 2.205

7.  Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Authors:  I Ourmanov; C R Brown; B Moss; M Carroll; L Wyatt; L Pletneva; S Goldstein; D Venzon; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge.

Authors:  A Seth; I Ourmanov; J E Schmitz; M J Kuroda; M A Lifton; C E Nickerson; L Wyatt; M Carroll; B Moss; D Venzon; N L Letvin; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

9.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation.

Authors:  Tasha Biesinger; Robert White; Monica T Yu Kimata; Brenda K Wilson; Jonathan S Allan; Jason T Kimata
Journal:  Retrovirology       Date:  2010-10-13       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.